PMC4671768_01
Fluorescein angiography and optical coherence tomography studies for case 1 (Irvine-Gass syndrome).. Notes: (A) Cystoid macular edema, macular contour, and macular thickness at presentation. (B and C) Reduced macular leakage on the fluorescein angiogram; reduced macular contour and thickness; and macular change analysis (B) 13 days following treatment and (C) 1 year following treatment. The difference maps are made between the intervals between the figures. The first difference map shows the difference between day 13 and day 0. The second difference map shows the difference between 1 year and day 13.. Abbreviations: T, temporal; N, nasal.
imcrj-8-305Fig1.jpg
PMC4671768_01_imcrj-8-305Fig1.jpg
f1-imcrj-8-305
Best-corrected visual acuity (BCVA) measured 20/100, intraocular pressure (IOP) was 16 mmHg, and fluorescein angiography (FA) studies revealed CME with disc leakage (Figure 1A). Optical coherence tomography (OCT) studies revealed cystic edema with a central macular thickness (CMT) of 424 microm (Figure 1A). CMT decreased 97 microm (Figure 1B). She is now maintained on nepafenac twice daily (BID) with a BCVA of 20/20 and CMT of 293 microm (Figure 1C).
PMC4671768_02
Fluorescein angiography and optical coherence tomography studies for case 2 (Irvine-Gass syndrome).. Notes: (A) Cystoid macular edema, macular contour, and macular thickness at presentation. (B) Macular contour and thickness and macular change analysis 14 days following treatment. (C) Decreased macular leakage; decreased macular contour and thickness; and macular change analysis 2 months following treatment.. Abbreviations: T, temporal; N, nasal.
imcrj-8-305Fig2.jpg
PMC4671768_02_imcrj-8-305Fig2.jpg
f2-imcrj-8-305
FA studies showed CME with disc leakage (Figure 2A) and OCT studies revealed cystic edema with a CMT of 461 microm (Figure 2A). After 14 days, BCVA measured 20/25 with a CMT of 294 microm, a 167 microm improvement (Figure 2B), and her IOP was controlled at 13 mmHg. After 3 additional months of continued treatment, her BCVA improved to 20/25 with CMT of 282 microm and reduction in CME (Figure 2C).
PMC4671768_03
Fluorescein angiography and optical coherence tomography studies for case 3 (Irvine-Gass syndrome).. Notes: (A) Cystoid macular edema, macular contour, and macular thickness at presentation. (B) Macular contour and thickness and macular change analysis 14 days following treatment. (C) Decreased macular leakage; decreased macular contour and thickness; and macular change analysis 3 months following treatment.. Abbreviations: T, temporal; N, nasal.
imcrj-8-305Fig3.jpg
PMC4671768_03_imcrj-8-305Fig3.jpg
f3-imcrj-8-305
OCT studies revealed cystic edema associated with a mild ERM and CMT of 375 microm (Figure 3A). After 14 days, BCVA measured 20/25 with CMT of 302 microm, a 73 microm improvement (Figure 3B), and IOP was unchanged at 13 mmHg. After 4 months of treatment, his BCVA stabilized at 20/25 and CMT measured 291 microm with a further 11 microm decrease in CMT (Figure 3C).
PMC4671768_04
Optical coherence tomography studies for case 4 (diabetic retinopathy).. Notes: (A) Macular contour and thickness at presentation. (B) Macular contour and thickness and macular change analysis 14 days following treatment. (C) Increased cystoid macular edema with cessation of treatment and (D) improvement with resumption of treatment.. Abbreviations: S, superior; I, inferior.
imcrj-8-305Fig4.jpg
PMC4671768_04_imcrj-8-305Fig4.jpg
f4-imcrj-8-305
BCVA measured 20/25-2, IOP was 12 mmHg, and OCT studies showed CME with a CMT of 284 microm (Figure 4A). After 14 days, BCVA remained 20/25-2, but his CMT had minimally improved by 9 microm and a reduction in the perifoveal cyst was noted (Figure 4B). There was consistent recurrence of CME after cessation of drops (Figure 4C) and improvement when the topical combination of drops was reinitiated (Figure 4D).
PMC4671768_05
Optical coherence tomography studies for case 5 (uveitis).. Notes: (A) Macular contour and thickness at presentation. (B) Macular contour, thickness, and macular change analysis (difference map) following treatment. Yellow asterisks indicate artifacts.. Abbreviations: T, temporal; N, nasal; OD, oculus dexter; OS, oculus sinister.
imcrj-8-305Fig5.jpg
PMC4671768_05_imcrj-8-305Fig5.jpg
f5-imcrj-8-305
CMT of 343 microm in the right eye and 372 microm in the left eye (Figure 5). Clinical exam revealed 1+ cells in the anterior chamber and 3+ in the vitreous in both eyes. CME was also confirmed with FA studies. After 2 weeks, BCVA was 20/40-2 in the right eye and 20/80-1 in the left eye, and CMT had decreased by 82 microm in the right eye and 93 microm in the left eye (Figure 5).
PMC4671768_06
Optical coherence tomography studies for case 6 (branch retinal vein occlusion).. Notes: (A) Macular contour and thickness at presentation. (B and C) Macular contour and thickness and macular change analysis (B) 7 days and (C) 90 days following treatment. (D) Increased cystoid macular edema with cessation of treatment and (E) improvement with resumption of treatment.. Abbreviations: T, temporal; N, nasal.
imcrj-8-305Fig6.jpg
PMC4671768_06_imcrj-8-305Fig6.jpg
f6-imcrj-8-305
OCT studies revealed CME with CMT of 356 microm (Figure 6A). OCT studies showed a 49 microm reduction in CMT and 74 microm reduction in perifoveal thickness with near resolution of the CME (Figure 6B). UCVA ultimately recovered to 20/20 in both eyes with IOP of 16 mmHg in the right eye and 14 mmHg in the left eye 3 months following treatment (Figure 6C). OCT study showed recurrent CME with a 44 microm increase in CMT and 82 microm increase perifoveally (Figure 6D). One month following treatment, the patient recovered to 20/20-1 in the right eye and 20/20 in the left eye (Figure 6E).